|
|
2.
|
Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. MedStar authors:
Year: 2018
Citation: - New England Journal of Medicine. 379(12):1107-1117, 2018 09 20.
Institution: - MedStar Heart & Vascular Institute
Medline publication type:
All authors: - Bohula EA, Bonaca MP, Brown C, Budaj A, CAMELLIA-TIMI 61 Steering Committee and Investigators, Dhadda S, Fanola CL, Francis B, Garcia-Castillo A, Gupta M, Im K, Inzucchi SE, Keech AC, Kuder J, Leiter LA, McGuire DK, Miao W, Patel T, Perdomo C, Qamar A, Ruff CT, Sabatine MS, Scirica BM, Smith SR, Weissman NJ, White HD, Wiviott SD
|
|
|
3.
|
Exploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS). MedStar authors:
Year: 2017
Citation: - Diabetic Medicine. 34(12):1747-1755, 2017 Dec.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Barrett-Connor E, Dabelea D, Dagogo-Jack S, Hamman RF, Kahn SE, Knowler WC, Mather KJ, Pan Q, Perreault L, The Diabetes Prevention Program Research Group
|
